Reportedly, the GAVI Vaccine Alliance to buy 200 million doses of Johnson & Johnson’s COVID-19 vaccine, as a major shortfall in the COVAX vaccine-sharing program is caused as India suspends vaccine exports. The country is fighting vaccine shortage and fails to fulfill its home demand as it fights the second wave of the pandemic.
“As a one dose vaccine, the J&J vaccine has particular relevance for places with difficult infrastructure, making it a very important addition to the portfolio,” stated GAVI CEO Seth Berkley said in a statement announcing the signing of an advanced purchase agreement with the U.S. drugmaker.
The Global Alliance for Vaccines and Immunization (GAVI) stated that the goal was to have the new J&J doses available in 2021, for distribution to both poorer countries, as well as self-financing participants of COVAX. COVAX, co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI), and WHO aims to secure 2 billion vaccine doses for lower-income countries by the end of 2021.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners, and eceive our FREE email updates throughout the week and view our exclusive content and research.
